Exhibit 99.1 ICU Medical Announces Fourth Quarter 2025 Results and Provides Fiscal Year 2026 Guidance SAN CLEMENTE, Calif., February 19, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended December 31, 2025. Conference Call Fourth Quarter 2025 Results Fourth quarter 2025 revenue was $540.7 million, as compared to $629.8 million in the same period in the pri ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 28, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36029 Sprouts Farmers Market, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of inc ...

Revenue Performance - Total revenue for Q4 2025 was $172.9 million, a 6.5% increase from $162.3 million in Q4 2024[4] - Revenue from material sales in Q4 2025 was $95.5 million, up from $93.3 million in Q4 2024, driven by higher unit material volume[4] - Revenue from royalty and license fees in Q4 2025 was $72.6 million, compared to $64.4 million in Q4 2024, reflecting increased unit material volume[4] - Full year 2025 total revenue was $650.6 million, slightly up from $647.7 million in 2024[7] - Full year 2025 revenue from material sales decreased to $353.0 million from $365.4 million in 2024, primarily due to changes in customer mix[7] - Full year 2025 revenue from royalty and license fees increased to $275.1 million from $266.8 million in 2024[7] Income and Profitability - Operating income for Q4 2025 was $67.2 million, compared to $52.5 million in Q4 2024, which included $8.9 million in restructuring costs[4] - Net income for Q4 2025 was $66.3 million, or $1.39 per diluted share, up from $46.0 million, or $0.96 per diluted share in Q4 2024[4] - Net income for the year ended December 31, 2025, was $242.1 million, up 9% from $222.1 million in 2024[22] - Operating income for the year ended December 31, 2025, was $248.6 million, an increase of 4.7% from $238.8 million in 2024[22] - Gross margin for Q4 2025 was $131.6 million, compared to $124.9 million in Q4 2024, reflecting a gross margin increase of 5.4%[22] Cash Flow and Dividends - Cash dividends declared per common share increased to $0.45 in Q4 2025 from $0.40 in Q4 2024, representing a 12.5% increase[22] - The company announced a cash dividend of $0.50 per share for Q1 2026, payable on March 31, 2026[11] - Net cash provided by operating activities for the year was $210.8 million, down from $253.7 million in 2024, a decrease of 16.9%[24] - The company reported a net cash used in investing activities of $45.5 million for the year, compared to $164.4 million in 2024[24] - Cash and cash equivalents at the end of 2025 were $138.4 million, up from $99.0 million at the end of 2024[24] Research and Development - Research and development expenses decreased to $38.5 million in Q4 2025 from $46.3 million in Q4 2024, a reduction of 16.0%[22] Future Outlook - The company expects 2026 revenue to be in the range of $650 million to $700 million, reflecting the dynamic OLED industry[10] Accounts Receivable - The company experienced a decrease in accounts receivable by $6.3 million in 2025, contrasting with an increase of $26.2 million in 2024[24]

Revenue Sources and Financial Performance - Farmer Mac's primary revenue sources include net interest income and guarantee fees from outstanding guaranteed securities and long-term standby purchase commitments (LTSPCs) [31]. - Net income attributable to common stockholders for 2025 was $182.5 million, a year-over-year increase of $2.1 million, driven by a $36.9 million increase in net interest income [203]. - Core earnings for 2025 were $182.9 million, reflecting an increase of $11.3 million year-over-year, primarily due to a $43.5 million increase in net effective spread [204]. - Net interest income for 2025 was $390.7 million, up $36.9 million from 2024, with a net interest yield of 1.19% [207]. - The company provided $10.5 billion in liquidity and lending capacity to lenders serving rural America during 2025 [201]. Loan and Credit Risk Management - The maximum loan size for eligible Agricultural Finance mortgage loans secured by more than 2,000 acres is $17.4 million as of December 31, 2025, with a cumulative direct credit exposure limit of 10% of Farmer Mac's Tier 1 capital, which is $170.6 million [36]. - The allowance for losses increased by $14.3 million, primarily due to $32.9 million in net provision expense, with significant credit deteriorations in Corporate AgFinance and Broadband Infrastructure segments [211]. - Substandard assets increased to $569.8 million as of December 31, 2025, representing 3.52% of the Agricultural Finance portfolio and 0.96% of the Infrastructure Finance portfolio [213]. - 90-day delinquency rates for Agricultural Finance loans were 0.40% as of December 31, 2025, compared to 0.37% in 2024 [214]. - The company has a concentration of $7.6 billion in AgVantage securities issued by three counterparties, which poses a significant credit risk if any of these counterparties default [128]. Business Operations and Market Position - The Agricultural Finance line of business includes the Farm & Ranch and Corporate AgFinance segments, which provide a secondary market for eligible loans through purchasing, guaranteeing, and servicing [34]. - Farmer Mac's activities aim to enhance lenders' liquidity and lending capacity, providing a stable funding source for agricultural and rural credit markets [29]. - The company markets a mix of products to lenders, including long-term fixed-rate loans, to meet their capital and liquidity needs [30]. - Farmer Mac's competitive position is influenced by the willingness of originators to offer eligible loans for sale in the secondary market, as well as the types of products offered by competitors [56]. - The company is classified within level I for compliance with capital standards as of December 31, 2025, indicating the highest compliance level [106]. Employee Engagement and Corporate Culture - As of December 31, 2025, Farmer Mac employed 212 people, reflecting a net increase of 21 employees (11%) compared to year-end 2024 [67]. - The company has a flexible office space and hybrid work model, which has enhanced employee engagement and contributed to receiving the USA Today Top Workplaces national award in 2025 [70]. - Farmer Mac's compensation and benefits package includes a robust paid time off program, a group health plan with all premiums paid by the company, and a 401(k) plan with employer contributions [72]. - The company has adopted a strategic learning and development program called "Farmer Mac LEARN," structured around six strategic LEARN Academies to support employee career development [71]. - The turnover rate decreased to 3.9% in 2025 from 6.8% in 2024 [76]. Capital Management and Financial Stability - As of December 31, 2025, the regulatory capital was $1.7 billion, exceeding the risk-based capital requirement of $201.3 million by approximately $1.5 billion [104]. - The company declared dividends of $1.50 per share for four quarters in 2025, with an increase to $1.60 scheduled for March 2026 [88]. - The company is authorized to borrow up to $1.5 billion from the U.S. Treasury to fulfill guarantee obligations, but has not utilized this authority as of December 31, 2025 [94][95]. - The company has a common stock repurchase program with an authorized amount of $50.0 million, extended to August 5, 2027 [90]. - The company must maintain a capital conservation buffer of more than 2.5% of risk-weighted assets, with restrictions on dividend payouts if the buffer falls below this level [113]. Risk Factors and Compliance - The company is subject to risks from geopolitical instability and natural disasters, which may adversely affect borrowers' ability to repay loans [119]. - The company faces risks from changes in U.S. trade policies and regulations that could impact agricultural producers and infrastructure borrowers [123]. - The company is regulated by government agencies, and changes in legislation could adversely affect its business operations and financial condition [161]. - The company may face increased compliance costs and legal liabilities due to evolving privacy and cybersecurity regulations [165]. - The company is exposed to operational risks due to reliance on third-party servicers for loan servicing, which could adversely affect business operations [142]. Cybersecurity and Operational Risks - Cybersecurity threats have increased, with the company facing regular attacks from various sources, which could disrupt operations and lead to significant financial losses [145]. - The company has implemented a comprehensive cybersecurity risk management program, including annual assessments and regular training for all employees [171]. - The cybersecurity subcommittee of the board meets monthly to discuss the performance and effectiveness of the cybersecurity program [177]. - The Chief Information Security Officer (CISO) has over 20 years of experience in cybersecurity and reports directly to the Chief Risk Officer [178]. - The company maintains a privacy and security incident response program to manage and recover from cybersecurity incidents [173].

As filed with the Securities and Exchange Commission on February 19, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____. Commission File Number 001-14951 FEDERAL AGRICULTURAL MORTGAGE CORPORATION (Exact na ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) Securities registered pursuant to Section 12(b) of the Act: | | | Registered | | --- | --- | --- | | Title of Each Class Common Stock, par value $0.001 per share | Trading Symbol(s) PLSE | Name of Each Exchange on Which The Nasdaq Stock Market LLC | ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Or ☐ TRANSITION REPO ...

Financial Performance - Full year 2025 revenue reached a record $1.1 billion, representing a 10% increase from $1.04 billion in 2024[4] - Q4 2025 revenue increased 8% to $300.3 million, compared to $278.7 million in Q4 2024[4] - Q4 subscription revenue grew by 12%, while enterprise AI revenue surged by 50%[1] - GAAP net income for 2025 was $39.4 million, or 3.4% of revenue, compared to a net loss of $(12.8) million in 2024[9] - Non-GAAP net income for 2025 was $228.7 million, or 19.9% of revenue, up from $185.3 million in 2024[9] - Adjusted EBITDA for 2025 was $269.7 million, or 23.5% of revenue, compared to $196.0 million, or 18.8% of revenue in 2024[9] - GAAP net income for Q4 2025 was $19.713 million, compared to $11.577 million in Q4 2024, representing a year-over-year increase of 70.5%[33] - Non-GAAP operating income for Q4 2025 reached $61.615 million, up from $49.519 million in Q4 2024, reflecting a growth of 24.5%[36] - Adjusted EBITDA for Q4 2025 was $77.322 million, which is 25.7% of revenue, compared to $64.256 million or 23.1% of revenue in Q4 2024[33] - The company reported a total revenue increase of 23.5% for the twelve months ended December 31, 2025, compared to the previous year[33] Cash Flow and Assets - Q4 2025 GAAP operating cash flow was $83.6 million, significantly higher than $49.8 million in Q4 2024[4] - Cash flows from operating activities for the twelve months ended December 31, 2025, were $226,207 thousand, up from $143,168 thousand in 2024[27] - Total current assets decreased to $959,724 thousand in 2025 from $1,248,568 thousand in 2024, reflecting a decline of 23.1%[21] - Total liabilities decreased to $1,004,253 thousand in 2025 from $1,429,022 thousand in 2024, a reduction of 29.7%[21] - The company reported a total stockholders' equity of $785,817 thousand as of December 31, 2025, an increase from $622,192 thousand in 2024[21] Future Projections - For full year 2026, revenue is expected to be in the range of $1.247 to $1.261 billion[10] - Q1 2026 GAAP net income per share is projected to be between $0.10 and $0.17[10] - GAAP net income for the three months ending March 31, 2026, is projected to be between $8,874 and $14,954, with a year-end estimate of $75,496 to $83,176 million[46] - Non-GAAP net income for the same period is expected to range from $50,820 to $53,900, with a year-end forecast of $245,700 to $250,380 million[46] - GAAP net income per share (diluted) is anticipated to be between $0.10 and $0.17 for the three months ending March 31, 2026, and $0.86 to $0.95 for the year[46] - Non-GAAP net income per share (diluted) is projected to be between $0.66 and $0.70 for the three months ending March 31, 2026, and $3.15 to $3.21 for the year[46] Expenses and Costs - Research and development expenses for Q4 2025 were $36,104 thousand, down from $41,480 thousand in Q4 2024, a decrease of 13.4%[24] - Total stock-based compensation for the twelve months ended December 31, 2025, was $148.068 million, down from $166.315 million in the previous year[43] - Acquisition and related transaction costs, along with one-time integration costs, are projected to be between $1,710 and $2,710 million for the three months ending March 31, 2026, and $7,563 to $8,563 million for the year[46] - Legal fees related to the securities class action are expected to be $400 million for both the three months and year ending March 31, 2026[46] Strategic Initiatives - Five9 emphasizes the importance of AI in transforming the customer experience market, positioning itself to lead in this area[5] - The company completed the acquisition of Acqueon Inc., impacting cash flows and strategic positioning in the market[27] - The company plans to continue its market expansion and product development initiatives in the upcoming fiscal year[33] - The adjusted EBITDA margin improved from 18.8% in 2024 to 23.5% in 2025, indicating enhanced operational efficiency[33] Guidance and Taxation - The company does not anticipate any material impact on its worldwide income tax provision due to the tax treatment of non-GAAP adjustments[48] - Guidance provided on February 19, 2026, should not be construed as an update or reaffirmation after that date[46]

Financial Performance - Prothena reported a net loss of $21.6 million for Q4 2025 and $244.1 million for the full year, compared to a net loss of $58.0 million and $122.3 million for Q4 and the full year of 2024, respectively [13]. - Total revenue for Q4 2025 was $21 thousand and $9.7 million for the full year, a significant decrease from $2.1 million and $135.2 million in Q4 and the full year of 2024, primarily due to collaboration revenue from Bristol Myers Squibb [14]. - Collaboration revenue for Q4 2025 was $21,000, compared to $2,123,000 in Q4 2024, reflecting a significant decrease [28]. - Total revenue for the year ended December 31, 2025, was $9,684,000, down from $135,157,000 in 2024 [28]. - The net loss for Q4 2025 was $21,589,000, compared to a net loss of $57,956,000 in Q4 2024 [28]. - Cash and cash equivalents decreased to $307,531,000 as of December 31, 2025, from $471,388,000 in 2024 [29]. - Total assets decreased to $326,804,000 in 2025 from $547,108,000 in 2024 [29]. - Total liabilities decreased to $46,330,000 in 2025 from $60,182,000 in 2024 [29]. Research and Development - Research and development (R&D) expenses decreased to $14.6 million for Q4 2025 and $134.9 million for the full year, down from $50.2 million and $222.5 million in the same periods of 2024 [15]. - Research and development expenses for Q4 2025 were $14,586,000, compared to $50,172,000 in Q4 2024 [28]. - Prothena's TDP-43 CYTOPE program demonstrated potential in preclinical models, with presentations at Neuroscience 2025 and the International Symposium on ALS/MND [11]. Clinical Trials and Partnerships - Roche's Phase 3 PARAISO trial for prasinezumab in early-stage Parkinson's disease is ongoing with primary completion expected in 2029, with peak sales potential greater than $3.5 billion [10]. - Novo Nordisk's Phase 3 CLEOPATTRA trial for coramitug in ATTR amyloidosis with cardiomyopathy is also ongoing, with primary completion expected in 2029 [10]. - Bristol Myers Squibb's Phase 2 TargetTau-1 trial for BMS-986446 in early Alzheimer's disease is fully enrolled, with primary completion expected in 1H 2027 [10]. - The company plans to report data from ongoing and future clinical trials, including those for prasinezumab and other technologies [27]. - The company has the potential to earn up to $105 million in aggregate clinical milestone payments from strategic partners in 2026 related to coramitug and PRX019 [21]. Future Outlook and Shareholder Actions - Prothena expects to use $50 to $55 million in net cash for operating and investing activities in 2026, ending the year with approximately $255 million in cash [21]. - The company anticipates a net cash burn from operating and investing activities for 2026, with an expected cash balance at the end of 2026 [27]. - Shareholders approved a reduction in share capital to create distributable reserves for a potential share redemption program in 2026 [22]. - The company is exploring the potential to return capital to shareholders through a share redemption program or other means [27].

RV Industry Participation - In 2024, nearly 10 million households reported at least one RV trip, indicating substantial RV participation despite a decline from pandemic-era peaks[30]. Marine Industry Performance - The total U.S. retail expenditures on boats, engines, accessories, and related costs fell by 2.6% to $55.62 billion in 2024 compared to 2023[32]. - Marine powerboat retail unit shipments decreased approximately 8% in 2025 compared to 2024, while marine wholesale unit shipments decreased approximately 4%[33]. Housing Market Trends - The manufactured housing (MH) industry wholesale unit shipments decreased to approximately 102,700 units in 2025 from approximately 103,300 units in 2024[39]. - In 2025, combined new housing starts decreased by 2% compared to the prior year, with single-family housing starts down by 7% and multifamily housing starts up by 12%[43]. Company Acquisitions and Financials - The Company completed acquisitions for aggregate cash consideration of approximately $117 million in 2025, totaling approximately $560 million over the last three years[46]. - The Company had approximately 4,500 active customers as of December 31, 2025, with sales to Forest River and Thor accounting for 28% of consolidated net sales in 2025[54]. - Purchases of property, plant, and equipment for 2025 amounted to $83 million, primarily for advanced manufacturing automation and equipment upgrades[48]. - The company’s total debt obligations under the 2024 Credit Agreement amounted to $192.2 million as of December 31, 2025, with a potential additional annual interest cost of approximately $1.9 million for a 100 basis point increase in SOFR rates[228]. Inventory and Production Management - The Company’s inventory levels are balanced with expected OEM production, and it continues to explore alternative sources of raw materials[58]. Innovation and Development - The Company’s Design/Innovation Center, The Studio, supports product development and recently introduced a new design and visualization service leveraging virtual reality[50]. Workforce and Human Capital Management - As of December 31, 2025, the company had approximately 10,000 team members, with 80% being hourly employees and 20% salaried employees[65]. - The company has implemented various human capital management programs, including free mental health assistance and tuition reimbursement, to support team members[66]. - The company’s leadership development programs aim to foster an inclusive culture and enhance team members' leadership skills[67]. Safety and Compliance - The company’s commitment to safety includes OSHA preparedness and ergonomic assessments to ensure a healthy work environment[70]. Seasonal Sales Trends - The company’s sales and profits are historically highest in the second quarter and lowest in the fourth quarter due to seasonal trends in the RV, marine, and powersports industries[64]. Market Risks and Financial Instruments - The company is exposed to commodity price volatility, particularly in key raw materials, but has generally been able to pass price adjustments to customers[229]. - The fair value of the company’s 1.75% Convertible Notes is subject to market risk, with potential increases or decreases based on the common stock price[230]. - The company has engaged in convertible note hedge transactions to reduce potential dilution upon conversion of the 1.75% Convertible Notes[232]. Leadership and Experience - The company’s executive team includes experienced leaders with extensive backgrounds in the RV, marine, and industrial sectors[69].

Media Contact: 858-366-6900 media@tandemdiabetes.com Investor Contact: 858-366-6900 IR@tandemdiabetes.com Exhibit 99.1 FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Financial Guidance San Diego, February 19, 2026 - Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and fiscal year ended December 31, 2025 and provided its financial guidanc ...